Prevalence of Hepatitis B in Insular Regions of Southeast China: A Community-Based Study

Ping Chen1, Chengbo Yu1, Bing Ruan1, Shigui Yang1, Jingjing Ren1, Weijian Xu2, Zhuanbo Luo1, Lanjuan Li1*

1 The State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, 2 School of Medicine, Zhejiang University, Hangzhou, China

Abstract

Objective: Hepatitis B virus (HBV) infection remains a significant public health problem. The purpose of this study was to investigate the seroepidemiology of HBV in people living in the insular regions, and to provide the most recent baseline data for planning and monitoring of health.

Methods: A cross-sectional, community-based survey was conducted without age restriction, on two isolated islands, Zhoushan and Yuhuan, China. The study sample was selected by random multistage cluster sampling. Serological samples and demographic information were collected from 15878 participants.

Results: The prevalences of anti-HBV core antibody (anti-HBc), hepatitis B virus surface antigen (HBsAg), and anti-HBV surface antibody (anti-HBs) were 33.1, 10.4, and 56.1%, respectively. We found statistically significant differences of HBV markers in men versus women (P<0.01). The prevalence of HBV infection increased with age. There were significant differences in the rates of HBsAg and anti-HBc positivity between the two islands (P<0.01). Alanine aminotransferase (ALT) levels were elevated (>38 IU/L) in 15.6% and 7.2% of the HBsAg-positive and negative groups, respectively. Elevated ALT levels were significantly higher in males (12.0%) compared with females (5.8%) (P<0.01). The α-fetoprotein (AFP) positivity rate was 0.6% in HBsAg-positive participants over the age of 30.

Conclusion: Due to the geographic location, we found that the HBV prevalence and potential for the development of hepatocellular carcinoma remained high in insular regions of southeast China, and are far above the national figures. Although a vaccination program has been in effect over the last 20 years, several additional measures should be adopted by the government to limit the spread of hepatitis B. These include the management of high risk persons and the floating population living on the islands, expansion of the immune population, and increased health education for fisherman.

Introduction

HBV infection remains a severe public health problem worldwide [1,2]. Each year around the world, HBV infection is responsible for about one million deaths due to liver failure, cirrhosis and more than 75% of the hepatocellular carcinomas world-wide develop from HBV infection [3,4].

Prior to 2006, China had been classified as an area with high prevalence of HBV [5]. According to a national study published in the early 1979, the overall prevalence of chronic HBV carriage was approximately 8.75% [6], which rose to 9.75% in 1992 [7]. Following recommendations from the WHO, the Expanded Program on Immunization (EPI) for infants was established in China in 1992, and caused a significant decline in HBV prevalence to 7.18% according to a national survey in 2006 [8]. Moreover, significant variations in the seroepidemiology of HBV across regions in China were found, with the highest rate observed in the mid-south, and lowest rate in northern China. The prevalence of HBsAg in Zhejiang Province, which is located in the south of China, was found to be over 11% in 1992, higher than the national rate, but had declined to 5.8% by 2001 [9].

In the insular regions of Zhejiang Province, due in part to a more developed economy, and a high floating population, the prevalence of HBsAg in the residents was found to be 19.33% in 1997, notably higher than that in Zhejiang Province as a whole [10]. Although the EPI, which started from 1992 in these islands, was considered a success in this region, an epidemiological study of 3657 randomly selected fishermen in the coastal islands of Zhejiang Province found that the prevalence of anti-HBc, a marker of active infection, was 15.5% in 2007 [11]. This prevalence rate, although slightly lower than in the past, is still much higher than that for the entire Zhejiang Province (6.75%) [12].
However, to date, there have been very few HBV seroepidemiological studies on isolated islands. The community positivity rate of HBsAg in this region, and related risk factors remain unknown. The purpose of this project was to conduct a community-based epidemiological study to determine the prevalence of HBV infection in two major islands of southeast China, and to provide the most recent baseline data for planning and monitoring of health.

Methods

Study Population and Sampling Strategy

With the support of the Mega-Project for National Science and Technology Development for the “11th Five-Year Plan of China”, and the Department of Health of Zhejiang Province, we conducted an investigation on two major islands of Zhejiang Province from October 2010 to March 2012. Two coastal municipalities were randomly chosen. From each municipality, we selected one insular-county/city (equivalent to a county). Zhoushan and Yuhuan are two isolated islands which are connected to the mainland by a bridge. Most of the people make a living by fishing. The towns/subdistricts in each region were divided into three levels according to economic development. In each level, one town/subdistrict was randomly selected. Finally, within each town/subdistrict, three villages/communities were also selected according to the economic level. A list of residents from the resident’s committee was obtained using a registration book.

After receiving appropriate training by the lead researchers for this study, the physicians of each participating hospital began to conduct medical examinations, interviews, and laboratory tests on subjects who volunteered for free medical and health examinations. Altogether, approximately 360 physicians from 18 hospitals in the two insular counties were invited by the Department of Health of Zhejiang Province to participate. All local residents and migrant workers who had lived on these islands for >3 months (i.e., moved to the area before July 1, 2010) were screened for inclusion. The final average participation rate was about 60% among all the participating sites. The information collected consisted of demographics (sex, age, occupation, nationality, and marital status), residency status, medical history (e.g., blood transfusion, hepatitis B, allergies), and laboratory tests (HBsAg, anti-HBs, anti-HBc, AFP, ALT assays, and liver ultrasound (US)). Patients who had been diagnosed with HCV, HDV, HIV, immunosuppression disorders, or were on antiviral therapy, had alcohol abuse, or other liver diseases were excluded from the study.

All participants provided informed written consent and the informed written consent from the next of kin on the behalf of the minors/children participants. The data were analyzed anonymously. The study was approved by the Ethics Committee of The First Affiliated Hospital at the School of Medicine of Zhejiang University.

Serological Testing

A 5 mL venous blood sample was collected from each participant using strict hygiene and safety guidelines. The patient demographic information, including name, sex, age, and district, were recorded. Blood samples were kept in a low temperature container (controlled from 4–10°C) and delivered to Adicon Clinical Laboratories (Hangzhou, China) on the same day for sample processing and serological testing.

Commercially available enzyme immunoassay kits (Acon Bio-tech Co., Hangzhou, China) were used for HBsAg, HBsAb, anti-HBc measurements. Verification of elevated test results was carried out by retesting the samples using the same kits. Only samples that were positive on both tests were considered to be true positives. For the purpose of analysis, HBsAg positivity was considered indicative of current HBV infection. Anti-HBs was used as an indicator of previous exposure to HBV. Isolated HBsAb positivity was taken to indicate successful HBV vaccination. Individuals who tested negative for all HBV serological markers were considered to be non-immune and non-infected.

Alanine Aminotransferase Levels and Hepatocellular Carcinoma Screening

ALT is the most commonly used enzyme in the evaluation of liver disease. Serum ALT quantitation was performed within 2 hr of arrival at the laboratories. Quantitation was achieved using a coupled enzyme and indicator reaction that utilizes pyruvate for a kinetic determination of NADH consumption measured by an Architect C8000 automated biochemical analyzer (Abbott Laboratories, Abbott Park, IL, USA). Abnormal ALT values were defined as greater than 38 IU/L, representing 2.25 SD above the mean for normal subjects. Verification of elevated test results was carried out by retesting the samples using the same kits. Only samples that were positive on both tests were considered to be true positives. HCC community-based preliminary screening was performed for HBsAg-positive subjects by detection of α-fetoprotein (AFP) and imaging of the liver by ultrasound (US). Qualitative α-fetoprotein (AFP) screening for HCC was performed on participants >30 years old (yo) who were HBsAg-positive, using an AFP EIA Test Kit (BoSai, Zhengzhou, China). Liver US was conducted by the doctors from the radiology department of each community health center. A preliminary diagnosis of HCC was made based on the presence of a positive AFP and a focal mass consistent with a tumor detected by US.

Data Analysis

Data were managed and analyzed using SPSS software version 17.0 (SPSS, Inc., Chicago, IL, USA). For categorical variables, we used the chi-square test to determine group differences. A P<0.01 was considered to be statistically significant. The HBsAg, anti-HBs and anti-HBc carrier rates were standardized by age and sex according to the 2010 Zhejiang population data [13] The 95% confidence intervals (CI) for the proportion of individuals who were HBsAg-positive, stratified by age and sex, as well as for the whole group, were calculated.

Results

Characteristics of the Study Group

A total of 15878 serum samples were tested. Information on age or sex was missing for 881 participants (5.5%). Thus, a total of 14997 samples were analyzed. To allow comparisons without distortion by age and sex, the prevalence was directly standardized to the age and sex distribution of all participants in the study population. In this study, the age groups and proportion of each were: <20 yo (29.34%), 20–29 yo (14.46%), 30–39 yo (20.08%), 40–49 yo (13.94%), 50–59 yo (10.38%), 60–69 yo (6.83%), and 70 yo (4.97%) with the same sex proportion [13]. Demographic characteristics of the study population are shown in Table 1.

Prevalence of HBV by Age and Sex

A total of 1763 individuals tested positive for HBsAg (Table 2). The prevalence of HBsAg positivity, a marker of current infection,
in this population was 10.4% (95% CI: 9.9–10.9). The infection rate increased gradually from 1.7% in those <20 yo to 17.0% in those 40–49 yo, reaching a peak in this decade of life, and declining thereafter (Table 2). The prevalence among male participants (12.0%; 95% CI: 11.2–12.8) was significantly higher (P<0.01) compared with that among female participants (8.8%; 95% CI: 8.3–9.3) (Figure 1). The prevalence of anti-HBc, a marker of HBV exposure, was 33.1% (95% CI: 32.4–33.8) overall, but did not vary significantly between the genders. The study showed that exposure increased with age both in males and in females, and reached a peak in the 40–49 yo group, declining thereafter, indicating exposure to HBV had occurred in all age groups (Figure 2). The prevalence of anti-HBs increased from 50.9% to 57.7% in the 20–69 yo group, and more than 60% among those ≥70 yo. Isolated anti-HBs, evidence of HBV vaccine-induced immunity, was found in approximately 39.3% (95% CI: 38.5–40.1) (Table 2).

Prevalence of HBV Stratified by Participant Islands

In Table 3, HBV prevalence was calculated according to participant gender in each district. The total prevalence was calculated by adjusting for the population of each island in addition to sex ratio. The prevalence of HBsAg was significantly higher (P<0.01) in the Zhoushan group (14.8%; 95% CI: 14.0–15.6) than in the Yuhuan group (9.1%; 95% CI: 8.4–9.8). On each island, the prevalence of HBsAg was higher in males than in females. The prevalence among male individuals in Zhoushan was 17.1% (95% CI: 15.7–18.5). The prevalence of anti-HBc was 43.3% and 35.7% in the Zhoushan and Yuhuan groups, respectively. The prevalence of anti-HBc in the Zhoushan group was significantly higher than in the Yuhuan group (P<0.01), whereas there was no significant difference between males and females on either island. The prevalence of anti-HBs showed a trend similar to the prevalence of HBsAg in the two island groups, with prevalences of 59.1% and 54.8% in the Zhoushan and Yuhuan groups, respectively. The prevalence of vaccination-induced immunity (isolated anti-HBs) was also higher (P<0.01) in the Zhoushan group (Table 3).
Hepatocellular Carcinoma Screening in the HBsAg Positive Group and ALT Levels

There were ten HBsAg-positive patients, three female and seven male, >30 yo (0.6%) who were AFP positive. However, no tumors were found by liver US. The mean (±SD) ALT was 21.1 (±19.0), and the proportion of participants with elevated ALT (≥38 IU/L) was 8.2%. The HBsAg-positive group had a significantly higher level of ALT (27.7 IU/L) compared with the HBsAg-negative group (21.0 IU/L). The proportion of patients with elevated ALT was significantly higher in the HBsAg-positive group (15.6%) compared with the HBsAg-negative group (7.2%) (P<0.01). In both HBsAg-positive and HBsAg-negative groups, the proportion with elevated ALT was significantly higher in male than in female participants (P<0.01) (Table 4). In all participants, the proportion of elevated ALT was markedly higher in males (12.0%) than in females (5.8%) (P<0.01). The male participant average ALT level (23.2 IU/L) was higher than that of the female participants (18.3 IU/L). The proportion of patients with elevated ALT significantly decreased with age, from 10.7% in the 40–49 yo group to 5.5% in the 70 yo group (P<0.01) (Figure 3).

Figure 2. Age-specific prevalence of anti-HBV core antibody (anti-HBc).

doi:10.1371/journal.pone.0056444.g002

Table 2. Prevalence of hepatitis B virus markers, stratified by age group.

| Age Group (Years) | Only anti-HBs | HBsAg | anti-HBc | anti-HBs |
|-------------------|---------------|-------|----------|----------|
| No. tested/ | % | No. tested/ | % | No. tested/ | % | No. tested/ | % |
| <20 | 943/1725 | 54.7 | 30/1725 | 1.7 | 132/1725 | 7.7 | 1019/1725 | 59.1 |
| 20–29 | 144/550 | 26.2 | 64/550 | 11.6 | 225/550 | 40.9 | 280/550 | 50.9 |
| 30–39 | 450/1439 | 31.3 | 206/1439 | 14.3 | 630/1439 | 43.8 | 777/1439 | 54.0 |
| 40–49 | 1038/3083 | 33.7 | 525/3083 | 17.0 | 1420/3083 | 46.1 | 1676/3083 | 54.4 |
| 50–59 | 1324/3637 | 36.4 | 487/3637 | 13.4 | 1596/3637 | 43.9 | 2099/3637 | 57.7 |
| 60–69 | 947/2648 | 35.8 | 307/2648 | 11.6 | 1194/2648 | 45.1 | 1504/2648 | 56.8 |
| ≥70 | 774/1915 | 40.4 | 144/1915 | 7.5 | 775/1915 | 40.5 | 1191/1915 | 62.2 |
| Total | 5620/14997 | 39.3 | 1763/14997 | 10.4 | 5972/14997 | 33.1 | 8546/14997 | 56.1 |

The proportion of individuals who were positive were standardized by age.

doi:10.1371/journal.pone.0056444.t002
Discussion

In Zhejiang Province, the EPI vaccination program is considered a success. Since program initiation in 1992, the high risk hepatitis B designation has moved from infants and children (0–9 yo) and adults (30–39 yo) to middle aged adults (40–49 yo) [14]. In the current study, the infection rate of insular residents 40–49 yo was the highest, which is consistent with the findings of a previous epidemiological study. It appears that government programs should continue to target island persons, particularly those in the 40–49 yo group, for HBV-related education, and screening to reduce HBV spread among a wider population.

The national HBsAg prevalence in individuals aged 1–59 yo has been reported to be 7.18% in 2006, which represents a 26.3% decrease from 9.75% in 1992. The rate of HBsAg positivity in insular regions of southeast China fell from 9.75% in 1997 to 15.5% in 2007, a reduction of 22.2%, which is similar to the trend in the rest of China. This may be related to the efficient implementation of the vaccination policy in China. Data obtained from the national survey in 2005 revealed that the HBV vaccination series completion rate of infants was approximately 90.7% in rural areas, and 95.0% in urban areas [15]. The completion rate in Zhejiang province reached 93.03% by 1997, and the coverage rate has increased over the years [16].

The rate of HBsAg positivity varies considerably in different regions of China. For example, the rate of HBsAg positivity in Guangdong Province is 12.45% [17], but only 3.49% in Beijing [18]. Our study demonstrated that HBV infection is still highly prevalent in insular regions.

### Table 3. Prevalence of HBV markers, stratified by region.

| Region | Only anti-HBs | HBsAg | anti-HBc | anti-HBs |
|--------|---------------|-------|----------|----------|
|        | No. positive/ | No. positive/ | No. positive/ | No. positive/ |
|        | no. test | %     | no. test | %     | no. test | %     | no. test | %     |
| Zhoushan Male | 1149/2818 | 40.8 | 481/2818 | 17.1 | 1228/2818 | 43.6 | 1675/2818 | 59.4 |
| Zhoushan Female | 2066/5528 | 37.4 | 697/5528 | 12.4 | 2371/5528 | 42.9 | 3224/5528 | 58.3 |
| Zhoushan Total | 3215/8346 | 39.1 | 1178/8346 | 14.8 | 3599/8346 | 43.3 | 4899/8346 | 59.1 |
| Yuhuan Male | 1110/2966 | 37.4 | 300/2966 | 10.1 | 1043/2966 | 35.2 | 1617/2966 | 54.5 |
| Yuhuan Female | 2405/3685 | 35.1 | 295/3685 | 8.0 | 1330/3685 | 36.1 | 2030/3685 | 55.1 |
| Yuhuan Total | 55.1/6651 | 36.3 | 595/6651 | 9.1 | 2373/6651 | 35.7 | 3647/6651 | 54.8 |

The proportion of individuals who were positive were standardized by gender.

Figure 3. Age-specific proportion of elevated alanine aminotransferase.

doi:10.1371/journal.pone.0056444.g003
than Yuhuan. Moreover, the large floating population in Zhejiang Province with a more developed economy and prosperous ports increases the difficulty of health education and management [25]. This indicates that in different insular regions, at least in part because of the differences in economic development and the floating population, the prevalence of hepatitis B is clearly different. Both these two areas were included in the EPI in 1992, whereas Zhoushan initiated immunization of children in the floating population in 1999 [26]. Yuhuan instituted immunization of children in 1992. This may explain the observed difference in anti-HBs prevalence between the two islands in the current study.

ALT levels were found to be significantly related to HBsAg status on the islands. The HBsAg-positive group had a higher level of elevated ALT compared with the HBsAg-negative group (15.6% vs. 7.2%; $p<0.01$). Abnormal ALT levels were significantly more frequent among HBsAg carriers than among those who were not.

The association between ALT and age or gender was also found in the current study, which agrees with previous studies which reported that males were associated with higher levels of ALT than females. However, unlike previous studies, we found that individuals ≥50 years did not have higher levels of ALT [27,28].

A population-based cohort study from Japan found that even virus-negative participants with an ALT level exceeding 30 IU/L had a statistically higher risk of HCC than virus-positive patients with an ALT level under 30 IU/L [29]. The latter comprised a large proportion of participants in the current study. However, most of them were asymptomatic. Therefore, it is important for patients to participate in periodic examinations by the government.

This is the first study in China to screen for hepatic tumors in isolated islands on the basis of AFP and liver US in the general community. Although no cases of HCC were identified, we found the prevalence of abnormal AFP among HBsAg-positive individuals aged ≥30 yo was 0.6%, far above the recently reported 0.2% found in Zhejiang Province as a whole [14]. Hepatocellular carcinoma is the fifth leading malignancy and the third most deadly disease worldwide. In China, 110,000 people die of liver cancer annually, and account for 45% of the deaths globally. Therefore, it is important for patients to participate in periodic examinations by the government.

The prevalence rate of anti-HBc on the islands increased significantly with age, as other studies have observed [20–22]. This indicates that horizontal transmission still plays an important role in China. In 20–29 yo individuals, up to 40% of people living on the islands have already been exposed to the HBV, confirming that HBV infection occurs at a high rate in early life.

The prevalence of HBsAg positivity was found to be significantly associated with gender (males: 21.9% vs. females: 14.7%; $P<0.01$) in the current study, which is consistent with previous observations [22–24]. This finding may reflect pathogenesis-related mechanisms involving sex hormones. However, it is also possible that the findings are related to differences in lifestyle or behavior between males and females, such as smoking, drinking, extensive social range, physical activity, dining out, hygiene, and sexual activity. Particularly in insular regions, the activity of fishing is male dominated. The fishermen spend a lot of time eating and living together at sea each year. They do not pay attention to hygiene and there are different lifestyles and diets compared to non-fishermen. Therefore, health education urgently needs to be adjusted to the fisherman’s lifestyle.

The study also compared the difference between the Zhoushan and Yuhuan groups, and showed that the positivity rate of HBsAg and anti-HBc in the Zhoushan group was higher than those of the Yuhuan group. Zhoushan is located in the north part of Zhejiang Province with a more developed economy and prosperous ports than Yuhuan. Moreover, the large floating population in Zhoushan increases the difficulty of health education and management [25]. This indicates that in different insular regions, at least in part because of the differences in economic development and the floating population, the prevalence of hepatitis B is clearly different. Both these two areas were included in the EPI in 1992, whereas Zhoushan initiated immunization of children in the floating population in 1999 [26]. Yuhuan instituted immunization of children in 1992. This may explain the observed difference in anti-HBs prevalence between the two islands in the current study.

Table 4. Number and proportion of elevated ALT in HBsAg positive and HBsAg negative groups.

| HBsAg-positive | HBsAg-negative |
|----------------|----------------|
| <38 IU/L | >38 IU/L | <38 IU/L | >38 IU/L |
| No.positive/ Mean | No.positive/ Mean | No. positive/ Mean | No. positive/ Mean |
| Serum | ALT±SD | ALT±SD | ALT±SD | ALT±SD |
| ALT | no. test | % | no. test | % | no. test | % | no. test | % |
| Male | 588/761 | 26.8 | 77.3 | 173/761 | 74.5 | 4500/5023 | 22.7 | 89.6 | 523/5023 | 60.4 | 10.4 |
| | ±27.3 | ±74.6 | ±7.4 | ±30.2 | |
| Female | 892/992 | 18.4 | 89.9 | 100/992 | 77.8 | 7791/8221 | 15.5 | 4.89 | 430/8221 | 55.4 | 5.2 |
| | ±7.1 | ±79.0 | ±6.7 | ±24.4 | |
| Total | 1480/1753 | 22.0 | 84.4 | 273/1753 | 75.7 | 12291/13244 | 15.6 | 92.8 | 953/13244 | 58.2 | 7.2 |
| | ±19.0 | ±76.1 | ±7.0 | ±27.8 | |

doi:10.1371/journal.pone.0056444.t004
regions may be lower than that reported. Second, HBV virological assessment including HBV DNA levels and HBV genotypes were not performed. We did not analyze the clinical features of hepatitis, including jaundice, fatigue, and hepatic failure, in our community-based population, which may be significant among individuals.

In conclusion, this community-based study of insular regions provides information that might be useful in the design and implementation of future prevention strategies. Due to the geographic location, we found that HBV prevalence and potential risk of development of hepatocellular carcinoma remained high in insular regions of southeast China, and far above the national rates. Although the vaccination program has been implemented over the past 20 years, hepatitis B infection remains a great challenge for disease control in China. According to our research results, the government needs to undertake more long-term measures, such as the management of the high risk people, the floating population living on the islands, expansion of the immune population, and improved health education for fishermen.

Acknowledgments

We thank Drs. Jing Yang, Ping Zhang and Wei-hang Ma of the Bureau of Health of Zhejiang Province, and the members of the Bureaus of Health of each county of Zhejiang Province, for supporting the data collection. We also gratefully acknowledge Drs. Yun-de Hou and Kai Zhao of the China Engineering Academy for their scientific support of this project.

Author Contributions

Conceived and designed the experiments: LL PC CY WW BR. Performed the experiments: PC WW SY JR. Analyzed the data: PC WX ZL. Contributed reagents/materials/analysis tools: LL PC BR. Wrote the paper: PC WX CY BR SY.

References

1. Liu J, Fan D (2007) Hepatitis B in China. Lancet 369: 1582–1583.
2. Torpy JM, Burke AE, Golub RM (2011) JAMA patient page. Hepatitis B. JAMA 305: 1500.
3. Ganem D, Prince AM (2004) Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med 350: 1118–1129.
4. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, et al. (2005) A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 34: 1329–1339.
5. Andre F (2000) Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine 18 Suppl 1: S20–22.
6. Chen YS, Wang XX, Shang PH (2007) The study of tendency of hepatitis B virus surface antigen in Chinese population. Chin J Exp Clin Infect Dis 1: 5.
7. Xia GL, Liu CB, Cao HL (1996) Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis B, A, C, D, and E virus infections in China, 1992. International Hepatology Communications 5: 62–73.
8. Liang X, Bi S, Yang W, Wang L, Cui G, et al. (2009) Epidemiological serosurvey of hepatitis B in China: declining HBV prevalence due to hepatitis B vaccination. Vaccine 27: 6530–6537.
9. Yao J (2004) Status and control strategy of viral hepatitis in Zhejiang Province. Bulletin. Hangzhou: Chinese Foundation for Hepatitis Prevention and Control.
10. Yu AJ, Yan HH (1997) Seroepidemiological analysis of prevalence of hepatitis B in Zhejiang Province. Science of Travel Medicine 1: 14–15.
11. Tang A, Wang JY, Yan JB, Zhang QT (2007) Multiple factors analysis of the hepatitis B virus infection of the fishermen. Zhonghua Jiao Yu Preven Med 6: 43–45.
12. Li Q, Jiang ZG, Tang XW, Shi W (2008) Monitoring results of hepatitis B in Zhejiang Province in 2007. Zhejiang Journal of Preventive Medicine 12: 18–19.
13. Statistics ZPBo (2011) The main data bulletin from the sixth national census in Zhejiang province in 2010. In: Statistics ZPBo, editor. Hangzhou.
14. Lu Z, Xie Y, Deng M, Zhou X, Ruan B (2011) Prevalence of hepatitis B in the southeast of China: a population-based study with a large sample size. Eur J Gastroenterol Hepatol 23: 695–700.
15. Cui YQ, Peng HT, Liang XF (2007) Analysis on new born hepatitis B immunization coverage and pregnant women hospital delivery rate in different region. Chin J Vaccines Immunization 13: 1–3.
16. Yao J, Yang JZ, Mo SH, Zhang Z, Mo ST, et al. (2006) Investigation on Immunization Coverage Rate and Immune Effect of Hepatitis B Vaccine among Newborns in Zhejiang Province. Chin J Vaccine Immunization 6: 132–135.
17. Wang M, Liu JH, Cai YS, Xu JM, Xu JX, et al. (2009) An investigation on the epidemiological characteristics of hepatitis B in Guangzhou. Chin J Epidemiol 30: 1317–1318.
18. Wu J, Zhang W, Han LL, Lin CY, Lin H, et al. (2007) A sero-epidemiological study on hepatitis B among general population in Beijing. Chin J Epidemiol 28: 555–557.
19. Yang SG, Wang B, Chen P, Yu CB, Deng M, et al. (2012) Effectiveness of HBV vaccination in infants and prediction of HBV prevalence trend under new vaccination plan: findings of a large-scale investigation. PLoS One 7: e47808.
20. Nguyen VT, McLaws ML, Dore GJ (2007) Highly endemic hepatitis B infection in rural Vietnam. J Gastroenterol Hepatol 22: 2093–2100.
21. Bwog J, Braka F, Makumbi I, Mishra V, Bakamutiisho B, et al. (2009) Hepatitis B infection is highly endemic in Uganda: findings from a national serosurvey. Afr Health Sci 9: 98–108.
22. Wang CS, Chang TT, Yao WJ, Chou P (2002) Comparison of hepatitis B virus and hepatitis C virus prevalence and risk factors in a community-based study. Am J Trop Med Hyg 66: 389–393.
23. Gogos CA, Fosika KP, Nikiforidis G, Avgiroidis K, Sakellaropoulos G, et al. (2003) Prevalence of hepatitis B and C virus infection in the general population and selected groups in South-Western Greece. Eur J Epidemiol 18: 551–557.
24. Pereira LM, Martelli CM, Merchán-Hamann E, Montarroyos UR, Braza MC, et al. (2009) Population-based multicentric survey of hepatitis B infection and risk factor differences among three regions in Brazil. Am J Trop Med Hyg 81: 240–247.
25. Chen K, Pu LY (2009) Analysis of epidemiological characteristics of viral Hepatitis from 2002 to 2007 in Zhejiang. Zhejiang Prev Med 5 1–2.
26. Fu YX (2002) Floating children in islands immunization management investigation. Zhejiang Prev Med 3: 49–50.
27. Hayashi J, Kashiwagi S, Ikematsu H, Nomura H, Kaiyama W, et al. (1988) Sex- and age-specific prevalences of HBsAg and anti-HBc among HBsAg carriers with or without liver function abnormalities in Okinawa, Japan. Microbiol Immunol 8: 843–50.
28. Chu CM, Sheen IS, Lin SM, Liaw YF (1993) Sex difference in chronic hepatitis B virus infection: studies of serum HBsAg and alanine aminotransferase levels in 10,431 asymptomatic Chinese HBsAg carriers. Clin Infect Dis 16: 709–713.
29. Ishiguro S, Inoue M, Tanaka Y, Mizokami M, Iwashita M, et al. (2009) Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan. Eur J Cancer Prev 18: 25–32.
30. Shi J, Zhu L, Liu S, Xie WF (2005) A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 92: 607–612.
31. Nguyen VT, Law MG, Dore GJ (2009) Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat 16: 453–463.